We've got a moment, so let's take a trip down memory lane for a second.

SmallCapFirm

5 Potential Catalysts Could Fuel This Past Champ (MYCOF) To A Near Term Burst

(US: MYCOF) - (Canada: MYCO)

March 4th

SCF Readers,

We've got a moment, so let's take a trip down memory lane for a second.

I've been keeping a close eye on a past champ. Previously brought to you back in January, this high flyer erupted for a 33% surge in the span of just a couple sessions.

Plus, based on a slew of recent, ground-breaking press releases along with multiple oversold leaning technicals that could be signaling potential for a healthy reversal, it's time to get it back on your radar again.

And have I been bringing some serious intraday/short term champs to your radar the past couple weeks.

Here are their run totals (approximate):

  1. 2/22/22 - 169% Intraday
  2. 2/28/22 - 13% Over Two Days
  3. 3/3/22 - 33% Intraday

Now for the meat and potatoes...

Humanity is in a very dark place right now.

In recent years we've been dealing with all types of anxiety-inducing issues, from war to famines to diseases and climate change.

But it feels like the pace was picked up in the pandemic.

Separation has come in all forms from our neighbors, our family, our churches, our schools, our friends, etc.

It has led to an increase in Anxiety, Stress, Addiction, Depression, and Suicides. (Source 1)

In the U.S., the CDC has reported that more than 50% of people will be diagnosed with a mental illness or disorder at some point in their lifetime. (Source 2)

Most people just don’t have the resources available or are unresponsive to current treatments on the market.

What the street’s been searching for is a company that has the types of material advantages that will make it a winner in the mental health industry.

I've discovered a company that has a world-class management and research team behind it, and an undeniably incredible market advantage at the research and API level.

*Mydecine Innovations Group Inc. (MYCOF)*

image

Mydecine Innovations Group is a biotechnology and digital technology company developing innovative first-and-second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and dr-ug development infrastructure.

Mydecine Innovations Group was founded in 2020 on the guiding principle that there is a significant unmet need and lack of Innovations in the mental health and treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction, and other mental health disorders.

Mydecine Innovations Group's business model combines clinical trials and data outcome, technology, scientific and regulatory expertise, focusing on psych-e-delic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way we treat mental health disorders.

And right now the company has a handful of potential breakout catalysts to know which include:

No. 1 - Positive Meeting With The FDA

No. 2 - Company Now About To Supply cGMP Products

No. 3 - Signing Of A Game-Changing LOI With The Newly Institute

No. 4 - Oversold Leaning Technicals Could Be Signaling Reversal Potential

No. 5 - Major Supercomputing Breakthrough

But more on those in a second...

Tackling the Addiction and PTSD Crisis

image

Dr-ug Development Highlights

  • Four lead dr-ug candidates with improved controllability delivery mechanisms, safety, stability, shelf-life
  • Ability to cultivate, extract, conduct R&D, import and export full cGMP certified pharmaceutical grade natural and synthetic psi-lo-cybin and other tryptamines
  • Enhancing first generation molecules as well as novel molecular design
  • Global clinical trials focused on safe, approved standards and solutions at 7 clinical sites
  • Team of small molecule dr-ug design experts from Novartis, Pfizer, University of Alberta, Yale, etc.
  • Exclusive with world’s first accredited CRO
  • Partnership with internationally recognized FDA consulting firm, The Weinberg Group
  • 6 pending patents covering thousands of inventions that can be layered and standardized to FDA guidelines to achieve the desired or controlled outcome
  • Strong network of partners, including John Hopkins University, Applied Pharmaceutical Innovation (API), University of Alberta, Institute of Mental Health Research.
  • Health Canada Scheduled 1 Dr-ugs and Substances Dealer’s License

Lead Dr-ug Candidates

image

Artificial Intelligence Dr-ug Discovery Program

  • AI/ML program ranked top 3 in the world globally
  • Launched in-silico dr-ug discovery program in conjunction with researchers at the University of Alberta
  • Developing artificial intelligence/machine learning (AI/ML) supported dr-ug screenings, including the ability to build dr-ugs from the receptor up and assess dr-ugs around the receptors
  • Combining AI with in-silico structural modeling to design novel Serotonin Receptors modulators
  • More rapidly screen hundreds of thousands of new molecules without the need to produce them as well as its proprietary library of novel compounds
  • Led by top computer-aided dr-ug development expert, Dr. Khaled Barakat
image

Milestones: 2021 and Beyond

image

More from the company presentation.

-----

And right now, the company has several potential catalysts that could spark vertical chart growth near term. Here's what you need to know...

No. 1 MYCOF Potential Breakout Catalyst - Positive Meeting With The FDA

Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study

Company rapidly prepares to submit IND and Breakthrough Therapy Status Applications

DENVER, March 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Dr-ug Administration (FDA) regarding their Investigational New Dr-ug (IND) and breakthrough therapy status applications.

The Company reported a meeting with the FDA on February 28th to review their IND application to administer MYCO-001, in combination with therapy, to humans as part of smoking cessation treatment. Leading dr-ug and substance abuse researcher, Dr. Matthew Johnson of Johns Hopkins University, will serve as the lead investigator for this multi-site study.

The data from John Hopkins University’s ongoing studies assessing psych-e-delic-assisted therapy to treat nic-o-tine addiction is showing efficacy rates 2-3 times higher than the current gold standard of treatment. Our team is eager to start collecting the data needed to bring an approved dr-ug product to market that could potentially save millions of lives,” said Mydecine Chief Medical Officer Dr. Rakesh Jetly.

"Mydecine plans to submit a request for Breakthrough Therapy designation with our IND submission. Psi-lo-cybin-assisted therapy has shown meaningful advantages over available medications for to-ba-cco addiction including significant increases in safety and efficacy. We are looking forward to closely working with the FDA to bring safer and more effective therapy to the millions of people who are trying to quit smoking across the globe,” said Mydecine’s Senior Director of Clinical and Regulatory Affairs, Jessica Riggleman.

We had an extremely positive meeting with the FDA in regards to our proposed smoking cessation study. The FDA provided helpful feedback on our study design that we will implement. We are now working rapidly in preparing our IND submission for the 2B portion of the study which we believe will be next month. Once cleared, we will move swiftly into patient recruitment. This is a study we have been diligently working on over the last two years and we’re excited to continue moving it forward,” said Mydecine CEO Josh Bartch.

Read the full article here.

-----

No. 2 MYCOF Potential Breakout Catalyst - Company Now About To Supply cGMP Products

Mydecine’s Exclusive Dealer Identified as Licensed Psi-lo-cybin and MD-MA Supplier in Canada

Mydecine now able to supply cGMP products to healthcare providers for patients with serious and life-threatening conditions through the Special Access Program

VANCOUVER, British Columbia, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that Health Canada has included the dealer’s license Mydecine operates under as a supplier for the Special Access Program, which allows healthcare providers to request specific dr-ugs for approved patients who have not responded to other available treatment options.

The licensed dealer facility, available to Mydecine through its exclusive agreement with Applied Pharmaceutical Innovation (API), contains a unique research and development infrastructure as well as a manufacturing facility in Edmonton, Canada. With the license, Mydecine is able to provide psi-lo-cybin and MD-MA that meet Current Good Manufacturing Practices (cGMP) through Health Canada’s Special Access Program (SAP). This program allows practitioners to request psi-lo-cybin and MD-MA for a patient with a serious or life-threatening condition where conventional treatments have failed, are unsuitable, or are generally not available in Canada.

While we will continue to advance the research of psych-e-delic-assisted psychotherapy through our clinical trials and dr-ug development process, we understand there are patients in need of treatments today. Through our dealer’s license, we can offer psi-lo-cybin and MD-MA to practitioners and clinics in Canada who want to offer these treatment options for patients in need,” said Mydecine Chief Medical Officer Dr. Rakesh Jetly.

[...]

Read the full article here.

-----

No. 3 MYCOF Potential Breakout Catalyst - Signing Of A Game-Changing LOI With The Newly Institute

Mydecine Signs LOI with The Newly Institute to Provide Psych-e-delic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

Under Mydecine’s recently announced Special Access Support and Supply Program, the Company will supply cGMP Psi-lo-cybin and MD-MA to The Newly. The companies will partner to co-develop protocols, therapy manuals, and training needed to treat patients who need specific care.

VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has signed a Letter of Intent (LOI) with The Newly Institute Inc. (“The Newly”), a Calgary, Alberta based company opening private inter-disciplinary mental health clinics across Canada, to collaborate on expanding psych-e-delic-assisted psychotherapy to patients.

The Newly offers rapid access outpatient programs providing innovative mental health, addiction and trauma therapies. The Newly opened its first location last year in Calgary and intends to open additional clinics in cities across Canada beginning in 2022. Mydecine and The Newly have world-class teams of medical and scientific experts positioning their companies to provide the highest quality and most responsible care to patients. Together, the companies will create the package of resources needed for patients and practitioners to successfully gain acceptance into Health Canada’s Special Access Program (SAP).

The Newly is the first partner under Mydecine’s recently announced Special Access Support and Supply Program (SASSP). The companies will develop protocols and therapy manuals for a variety of indications. Mydecine will provide cGMP psi-lo-cybin and MD-MA alongside the safety and efficacy data needed to gain acceptance into Health Canada’s SAP. The Newly will provide the clinic locations and experienced therapists needed to perform the treatments. The companies intend to enter into a revenue sharing agreement.

[...]

Mydecine Chief Medical Officer Dr. Rakesh Jetly said, “The recent changes to Canada's SAP program are encouraging, but in order to make a significant positive impact on patients, we need to ensure these therapies are carried out safely and effectively. We are excited to work hand-in-hand with The Newly team to develop the evidence-based protocols, therapy manuals, training and other resources physicians need in order to promote the successful integration of these treatments into their existing infrastructure."

[...]

Read the full article here.

-----

No. 4 MYCOF Potential Breakout Catalyst - Oversold Leaning Technicals Could Be Signaling Reversal Potential

As of close on Thursday, Barchart was reporting this profile to have several oversold leaning technicals.

These technicals could be signaling a healthy reversal in the near term.

Here's the definition of a "reversal" from Investopedia:

"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."

Now, here are some of the key technicals (as of close Thursday) that could signal MYCOF to be leaning oversold and on the verge of a potential reversal.

  • 9-Day Relative Strength Index: 30.69%
  • 14-Day Relative Strength Index: 35.14%

When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.

  • 14-Day Raw Stochastic: 10%
  • 14-Day Williams %R: 90%

As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.

Keep an eye on these technicals closely.

-----

No. 5 MYCOF Potential Breakout Catalyst - Major Supercomputing Breakthrough

Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psych-e-delic Dr-ug Development Enabling Quick Screening of Billions of Compounds

The new serotonin receptor model (5-HT2A) will allow the Company to rapidly increase dr-ug analysis promoting near-term patent filings for novel psych-e-delic molecules.

DENVER, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today they have completed a target-based model of the classic psych-e-delic serotonin receptor 5-HT2A for use in their AI-driven dr-ug discovery program. The new model will allow them to expeditiously screen billions of structures to determine which novel compounds are most likely to increase binding affinity, enabling them to continue creating improved second and third generation psych-e-delic molecules for medical use.

By centering their dr-ug discovery efforts around artificial intelligence (AI) and machine learning (ML), Mydecine is positioned to discover dr-ug enhancements more cost effectively and more efficiently than their competitors. Using AI technology is relatively new in the dr-ug development space and its applications are continuously expanding. The goal of this technology is to eliminate, or drastically reduce, the manual efforts companies typically undergo to identify possible dr-ug improvements. By filtering the dr-ug candidates with AI, the Company is inherently making their investments in later stage dr-ug development more valuable by eliminating potential candidates that are likely to fail early on in the process.

Without AI and ML, based on their hypotheses, companies have to manually synthesize each molecule and individually test the likelihood of a successful binding agent. This process can consume enormous amounts of time and money; therefore, efficiently eliminating candidates likely to fail in preference for candidates that are more promising is extremely valuable.

AI gives us an incredibly robust tool for screening potential novel psych-e-delic compounds. This screening gives us increased confidence in investing in the later stages of our dr-ug development and enables rapid development in our pipeline,” said Chief Science Officer Rob Roscow.

[...]

Read the full article here.

-----

MYCOF Potential Catalysts Recap - Key Details To Know

No. 1 - Positive Meeting With The FDA

No. 2 - Company Now About To Supply cGMP Products

No. 3 - Signing Of A Game-Changing LOI With The Newly Institute

No. 4 - Oversold Leaning Technicals Could Be Signaling Reversal Potential

No. 5 - Major Supercomputing Breakthrough

-----

Coverage is officially reinitiated on MYCOF. When you have time, do this:

image

Get MYCOF on your radar now.

Sincerely,

Axel Adams

Editor, SCF


Source 1
Source 2


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and JBN Partners LLC, SmallCapFirm has been hired for a period beginning on 1/12/22 and ending on 1/13/22 to publicly disseminate information about (MYCOF) via Website, Email and SMS. SWN Media LLC was paid fifteen thousand USD via bank wire transfer. SWN Media LLC owns zero shares of (MYCOF). Pursuant to an agreement between SWN Media LLC and JBN Partners LLC, SmallCapFirm has been hired for a period beginning on 3/4/22 and ending on 3/7/22 to publicly disseminate information about (MYCOF) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. StockWireNews owns zero shares of (MYCOF). To date we have been compensated a total of forty thousand USD via bank wire transfer to disseminate information about (MYCOF).